Roche develops unique PCR tests to detect the monkeypox virus

Roche and its subsidiary TIB Molbiol  have developed three different  LightMix ® Modular Virus kits for the detection of the monkeypox virus  Multiple clusters of monkeypox virus have been reported in non-endemic countries, and the World Health Organization (WHO) expects more cases will be identified as surveillance expandsUse of these new research test kits assess the spread of the virus and can help monitor the potential impact of therapeutics, vaccines and public health interventionsBasel, 25 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed three unique LightMix® Modular Virus kits in response to recent monkeypox virus concerns.  Multiple clusters of the monkeypox virus have been reported within the past two weeks in several European countries and North America, which are regions where the virus is not normally found.“Roche has very quickly developed a new suite of tests that detect the monkeypox virus and aid in following its epidemiologic spread,” said Thomas Schinecker, CEO Roche Diagnostics. “Diagnostic tools are crucial for responding to and ultimately controlling emerging public health challenges as they advance response measures such as tracing efforts and treatment strategies.” The first LightMix Modular Virus kit detects orthopoxviruses, including all monkeypox viruses from both the West African and Central African forms of the virus (referred to as clades).The second kit is a spe...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news